PAX-8 (SP348) Rabbit Monoclonal Antibody
Specialties: Anatomic Pathology
PAX-8 is a transcription factor expressed during embryonic development of Müllerian organs, kidney, and thyroid, with continued expression in neoplastic transformation of some epithelial cell types of these mature tissues.1 It can be useful for marking several types of carcinoma including, but not limited to, ovarian serous carcinoma, clear cell renal cell carcinoma and papillary thyroid carcinoma.1-5 Certain anti-PAX-8 antibodies may react with lymphocytes and their neoplasms, which has been attributed to cross-reactivity with PAX-5 due to sequence homology between PAX-8 and PAX-5, but clone SP348 does not exhibit reactivity in these cell types.6
- Ozcan A, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011; 24:751-64.
- Laury AR, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011; 35:816-26
- Nonaka D, et al. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008; 32:1566-71
- Nonaka D, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (Fox E1) in thyroid epithelial neoplasms. Mod Pathol. 2008; 21:192-200.
- Tong GX, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009; 22:1218-27
- Moretti L, et al. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012; 25:231-6.
Specifications
- Reactivity: paraffin
- Control: Renal cell carcinoma (Nuclear); Ovarian serous carcinoma (Nuclear); Papillary thyroid carcinoma (Nuclear); Fallopian Tube (Nuclear)
- Dilution Range: 1:10-1:20 *
Package Inserts
IFU
- IVD Rev. 0.0 (CMC36333000)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 363R-30 |
| 0.1 mL concentrate | 363R-34 |
| 0.5 mL concentrate | 363R-35 |
| 1.0 mL concentrate | 363R-36 |
| 1.0 mL predilute ready-to-use | 363R-37 |
| 7.0 mL predilute ready-to-use | 363R-38 |
For research use only (RUO) in Canada
| 25.0 mL predilute ready-to-use (RUO) | 363R-30-RUO |
| 0.1 mL concentrate (RUO) | 363R-34-RUO |
| 1.0 mL concentrate (RUO) | 363R-36-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 363R-37-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 363R-38-RUO |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 363R-30 |
| 0.1 mL concentrate | 363R-34 |
| 0.5 mL concentrate | 363R-35 |
| 1.0 mL concentrate | 363R-36 |
| 1.0 mL predilute ready-to-use | 363R-37 |
| 7.0 mL predilute ready-to-use | 363R-38 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 363R-30-RUO |
| 0.1 mL concentrate (RUO) | 363R-34-RUO |
| 1.0 mL concentrate (RUO) | 363R-36-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 363R-37-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 363R-38-RUO |
To request information on this product in additional countries, please click the button below.
